Physician profile
Brian E Coyle
NPI 1649244724
$1,330.48
in general payments reported to CMS, 2019-2025
16 companies · $15.00 in 2025
The $15.00 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $410 · 2020: $43.87 · 2021: $299 · 2022: $331 · 2023: $231 · 2025: $15.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $246.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $246.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $281.78 | 2019-2022 | |
| Sanofi Pasteur INC. | $279.58 | 2019-2023 | |
| Glaxosmithkline, LLC. | $164.94 | 2019-2025 | Pediarix, Bexsero |
| Cranial Technologies, INC | $108.45 | 2021-2023 | Doc Band |
| Merck Sharp & Dohme LLC | $94.57 | 2019-2023 | Vaqta, Vaxneuvance, Vaxelis |
| Genentech USA, INC. | $79.90 | 2019-2020 | |
| Pfizer INC. | $65.73 | 2021-2023 | |
| Ironshore Pharmaceuticals INC. | $40.43 | 2019 | |
| Tris Pharma INC | $37.60 | 2019 | |
| Seqirus USA INC | $35.76 | 2022-2023 | Flucelvax Quadrivalent |
| Arbor Pharmaceuticals, INC. | $35.32 | 2019 | |
| Neos Therapeutics, Lp | $33.70 | 2019 | |
| Aimmune Therapeutics, INC. | $21.34 | 2023 | |
| Sobi, INC | $19.74 | 2022 | |
| Alk-Abello, INC | $19.46 | 2023 | Grastek, Ragwitek, Odactra |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adlon Therapeutics L.P. | $12.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Coyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.